2001
Reactivity of dog sera to whole-cell or recombinant antigens of Borrelia burgdorferi by ELISA and immunoblot analysis
Magnarelli LA, Levy SA, Ijdo JW, Wu C, Padula SJ, Fikrig E. Reactivity of dog sera to whole-cell or recombinant antigens of Borrelia burgdorferi by ELISA and immunoblot analysis. Journal Of Medical Microbiology 2001, 50: 889-895. PMID: 11599738, DOI: 10.1099/0022-1317-50-10-889.Peer-Reviewed Original ResearchConceptsEnzyme-linked immunosorbent assayWhole cell antigenRecombinant antigensB. burgdorferiNon-vaccinated dogsPolyvalent enzyme-linked immunosorbent assaysCanine borreliosisTick-infested areasTotal immunoglobulinWhole-cell B. burgdorferiAntibody titresBorrelia burgdorferi sensu strictoVaccinated dogsJoint disordersImmune responseBurgdorferi sensu strictoAntigenImmunosorbent assaySerumDogsNatural infection
1996
Safety, efficacy, and immunogenicity of a recombinant Osp subunit canine Lyme disease vaccine
Ma J, Hine P, Clough E, Fish D, Coughlin R, Beltz G, Shew M. Safety, efficacy, and immunogenicity of a recombinant Osp subunit canine Lyme disease vaccine. Vaccine 1996, 14: 1366-1374. PMID: 9004447, DOI: 10.1016/s0264-410x(96)00045-x.Peer-Reviewed Original ResearchConceptsCanine Lyme disease vaccineLyme disease vaccineDisease vaccineGeometric mean antibody titersInjection site swellingMean antibody titersTypical clinical signsMonths postchallengeVaccination timeSecond vaccinationBorrelial antigensSpirochetal antigensAntibody titersProtective efficacyControl beaglesAdverse reactionsVaccinated dogsClinical signsImmunological memoryLocal reactionsAntibody productionNormal beaglesVaccinatesLyme diseaseOsp A
1995
Serologic responses of dogs naturally exposed to or vaccinated against Borrelia burgdorferi infection.
Barthold S, Levy S, Fikrig E, Bockenstedt L, Smith A. Serologic responses of dogs naturally exposed to or vaccinated against Borrelia burgdorferi infection. Journal Of The American Veterinary Medical Association 1995, 207: 1435-40. PMID: 7493871, DOI: 10.2460/javma.1995.207.11.1435.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, BacterialBacterial Outer Membrane ProteinsBacterial ProteinsBacterial VaccinesBiological AssayBlotting, WesternBorrelia burgdorferi GroupDog DiseasesDogsEnzyme-Linked Immunosorbent AssayFemaleImmune SeraImmunoglobulin GImmunoglobulin MLyme DiseaseMaleMiceMice, Inbred C3HVaccinationConceptsSerologic responseAntibiotic treatmentVaccinated dogsRecombinant outer surface proteinPassive protective activityBorrelia burgdorferi infectionMeans of ELISAImmunoblot analysisSeronegative dogsClinical responseSerologic testingClinical criteriaControl dogsAntibody responseMouse protectionB burgdorferiClinical trialsBurgdorferi infectionInfected dogsELISA titersProtective activityOuter surface proteinsUseful antigenDogsBorrelia burgdorferiProtection of Dogs from Lyme Disease with a Vaccine Containing Outer Surface Protein (Osp) A, OspB, and the Saponin Adjuvant QS21
Coughlin R, Fish D, Mather T, Ma J, Pavia C, Bulger P. Protection of Dogs from Lyme Disease with a Vaccine Containing Outer Surface Protein (Osp) A, OspB, and the Saponin Adjuvant QS21. The Journal Of Infectious Diseases 1995, 171: 1049-1052. PMID: 7706788, DOI: 10.1093/infdis/171.4.1049.Peer-Reviewed Original ResearchConceptsProtection of dogsAdjuvant QS21Vaccinated dogsControl dogsLyme diseaseIxodes scapularisOuter surface protein ABorrelia burgdorferi infectionB. burgdorferiSurface protein ADogsBurgdorferi infectionVaccineScapularisQS21InfectionDiseaseProtectionXenodiagnosisBurgdorferiProtein AFeverSymptomsLimp
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply